公开(公告)号：US09505785B2

公开(公告)日：2016-11-29

申请号：US14059626

申请日：2013-10-22

Applicant: GILEAD CONNECTICUT, INC. ,  GENENTECH, INC.

Inventor： Antonio J. M. Barbosa ,  Peter A. Blomgren ,  Kevin S. Currie ,  Ravi Krishnamoorthy ,  Jeffrey E. Kropf ,  Seung H. Lee ,  Scott A. Mitchell ,  Daniel Ortwine ,  Aaron C. Schmitt ,  Xiaojing Wang ,  Jianjun Xu ,  Wendy Young ,  Honglu Zhang ,  Zhongdong Zhao ,  Pavel E. Zhichkin

IPC: C07D519/00 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/551 ,  A61K45/06 ,  C07D471/14

CPC classification number: C07D519/00 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/551 ,  A61K45/06 ,  C07C69/65 ,  C07D209/52 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07F5/04

Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US10344040B2

公开(公告)日：2019-07-09

申请号：US15905363

申请日：2018-02-26

Applicant: GILEAD CONNECTICUT, INC. ,  GENENTECH INC.

Inventor： Antonio J. M. Barbosa ,  Peter A. Blomgren ,  Kevin S. Currie ,  Ravi Krishnamoorthy ,  Jeffrey E. Kropf ,  Seung H. Lee ,  Scott A. Mitchell ,  Daniel Ortwine ,  Aaron C. Schmitt ,  Xiaojing Wang ,  Jianjun Xu ,  Wendy Young ,  Honglu Zhang ,  Zhongdong Zhao ,  Pavel E. Zhichkin

IPC: C07D487/04 ,  C07D519/00 ,  C07D495/04 ,  C07D498/04 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/551 ,  A61K45/06 ,  C07D471/14 ,  C07C69/65 ,  C07D209/52 ,  C07F5/04

Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US10053469B2

公开(公告)日：2018-08-21

申请号：US15281923

申请日：2016-09-30

Applicant: GILEAD CONNECTICUT, INC. ,  GENENTECH INC.

Inventor： Antonio J. M. Barbosa ,  Peter A. Blomgren ,  Kevin S. Currie ,  Ravi Krishnamoorthy ,  Jeffrey E. Kropf ,  Seung H. Lee ,  Scott A. Mitchell ,  Daniel Ortwine ,  Aaron C. Schmitt ,  Xiaojing Wang ,  Jianjun Xu ,  Wendy Young ,  Honglu Zhang ,  Zhongdong Zhao ,  Pavel E. Zhichkin

IPC: C07D519/00 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/551 ,  A61K45/06 ,  C07D471/14 ,  C07C69/65 ,  C07D209/52 ,  C07F5/04

CPC classification number: C07D519/00 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/551 ,  A61K45/06 ,  C07C69/65 ,  C07D209/52 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07F5/04

Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.